You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,003,762

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,003,762

Title:	Monoclonal antibody to CD166 and method for production thereof
Abstract:	CD166 is a cell adhesion molecule belonging to an immunoglobulin superfamily that is expressed in an excessive amount on the tumor surface. If an monoclonal antibody specifically binding to the CD166 is obtained, it becomes possible to suppress growth of tumor cells, detect the cells, and supply a therapeutic drug thereto specifically. However, because the CD166 proteins are very similar to each other among mammals, it was not possible to obtain an antibody to human CD166, by immunizing, for example, mice with the human CD166. The antibody was prepared by immunizing mice with a purified avian CD166 protein. The antibody was found to be adsorbed on human and mouse CD166 proteins in vitro as well as in vivo and to have an action to suppress tumor growth in mice.
Inventor(s):	Tsukamoto; Yasuhiro (Takatsuki, JP)
Assignee:	Japan Science and Technology Agency (Saitama, JP) Osaka Prefecture University Public Corporation (Osaka, JP)
Application Number:	12/085,674
Patent Claims:	1. A monoclonal antibody, which specifically binds to the amino acid sequence of SEQ ID NO: 1 of cell adhesion molecule CD166/ALCAM. 2. The monoclonal antibody according to claim 1, wherein the subclass of the monoclonal antibody is immunoglobulin G. 3. A hybridoma, which produces the monoclonal antibody of claim 1. 4. A method of producing a monoclonal antibody, comprising purifying antibodies obtained from a mouse immunized with the amino acid sequence of SEQ ID NO: 1 to obtain a monoclonal antibody. 5. A method of measuring the level of CD166 in a sample, comprising contacting the monoclonal antibody according to claim 1 with the sample to thereby measure the level of CD166.

Details for Patent 8,003,762

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	12/12/2018	⤷ Try a Trial	2025-11-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.